Satellos nominates SAT-3247 as lead treatment candidate for DMD

Satellos Bioscience is hoping to bring SAT-3247, its newly nominated lead treatment candidate for Duchenne muscular dystrophy (DMD), into clinical trials next year. The company announced that it’s working to establish a good manufacturing practice (GMP) setup to make the medication, and is in the midst of experiments…

Lack of Signaling Protein Prevents Normal Muscle Tissue Formation, Study Shows

The absence of a signaling protein leads to immature muscle cells being unable to fuse together to promote muscle tissue growth, a study shows. University of Louisville researchers said lack of the MyD88 signaling protein prevented immature muscle cells known as myoblasts from fusing. When the protein’s levels are normal,…